|
| << previous | next >> |
Journal description
All volumes of the corresponding journal
All issues of the corresponding volume
All articles of the corresponding issues
Details for article 23 of 43 found articles
| Title: |
Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial |
| Author: |
Vano, Yann-Alexandre Elaidi, Réza Bennamoun, Mostefa Chevreau, Christine Borchiellini, Delphine Pannier, Diane Maillet, Denis Gross-Goupil, Marine Tournigand, Christophe Laguerre, Brigitte Barthélémy, Philippe Coquan, Elodie Gravis, Gwenaëlle Houede, Nadine Cancel, Mathilde Huillard, Olivier Beuzeboc, Philippe Fournier, Laure Méjean, Arnaud Cathelineau, Xavier Doumerc, Nicolas Paparel, Philippe Bernhard, Jean-Christophe de la Taille, Alexandre Bensalah, Karim Tricard, Thibault Waeckel, Thibaut Pignot, Géraldine Braychenko, Elena Caruso, Stefano Sun, Cheng-Ming Verkarre, Virginie Lacroix, Guillaume Moreira, Marco Meylan, Maxime Bougouïn, Antoine Phan, Letuan Thibault-Carpentier, Christelle Zucman-Rossi, Jessica Fridman, Wolf Herman Sautès-Fridman, Catherine Oudard, Stéphane |
| Appeared in: |
Lancet oncology |
| Paging: | Volume 23 () nr. 5 pages 612-624 |
| Year: |
2022 |
| Contents: | |
| Publisher: |
Elsevier Ltd |
| Source file: |
Elektronische Wetenschappelijke Tijdschriften |
Details for article 23 of 43 found articles
| << previous | next >> |
Toegankelijkheidsverklaring